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Ischemic stroke is associated with the pro-
inflammatory potential of N-glycosylated
immunoglobulin G
Di Liu1, Zhongyao Zhao1, Anxin Wang1,2, Siqi Ge1,3, Hao Wang1,3, Xiaoyu Zhang1, Qi Sun1, Weijie Cao1, Ming Sun1,
Lijuan Wu1, Manshu Song1, Yong Zhou4, Wei Wang1,3 and Youxin Wang1,3*
Abstract
Background: Glycosylation significantly affects protein structure and function and thus participates in multiple
physiologic and pathologic processes. Studies demonstrated that immunoglobulin G (IgG) N-glycosylation associates
with the risk factors of ischemic stroke (IS), such as aging, obesity, dyslipidemia, type 2 diabetes, and hypertension.
Methods: The study aimed to investigate the association between IgG N-glycosylation and IS in a Chinese population.
IgG glycome composition in patients with IS (n = 78) and cerebral arterial stenosis (CAS) (n = 75) and controls (n = 77)
were analyzed by ultra-performance liquid chromatography.
Results: Eleven initial glycans and 10 derived glycans in IgG glycome representing galactosylation, sialylation, and
bisecting GlcNAc significantly differed between IS patients and CAS and healthy controls after controlling for gender,
age, obesity, diabetes, hypertension, and dyslipidemia. Logistic regression models incorporating IgG glycan traits were
able to distinguish IS from CAS (area under receiver–operator characteristic curves (AUC), 0.802; 95% confidence
interval (CI), 0.732–0.872) and controls (AUC, 0.740; 95% CI, 0.661–0.819). The canonical correlation analysis indicated
that initial N-glycan structures are significantly correlated with inflammation markers (r = 0.566, p < 0.001).
Conclusion: Our findings indicated that loss of galactose and sialic acid, as well as addition of bisecting GlcNAc, might
involve in pro- or anti-inflammatory IgG functionality and further contribute to the pathogenesis of IS. IgG glycan profiles
may be developed as clinical useful biomarkers for chronic disease in the future.
Keywords: Ischemic stroke, Cerebral arterial stenosis, Immunoglobulin G, N-glycans, Inflammation markers
Background
Stroke is one of the leading causes of death and perman-
ent disability worldwide [1, 2]. Approximately 80% of
stroke is ischemic, whereas 20% is due to primary
hemorrhage [3]. Ischemic stroke (IS) is a multifactorial
and complicated disease, resulting from an intricate
interplay between environmental and genetic factors [3].
Cerebral arterial stenosis (CAS) of the major arteries in
the brain is one of the most common pathomechanisms
for the development of ischemic stroke [4]. There is a
pressing need for better understanding and prevention
of CAS. CAS and IS are characterized by a pro-
inflammatory state and elevated levels of markers of
inflammation, such as C-reactive protein and
interleukin-6, which are associated with the risk of CAS
and IS [5–8]. Although increasing evidence has indicated
that inflammation is important in the progression of
CAS to IS [7, 8], and numerous risk factors have been
identified, the underlying mechanisms of IS remain
largely unknown.
By attaching to individual proteins, glycans participate
in many key biological processes, including cell adhe-
sion, molecular trafficking and clearance, receptor acti-
vation, signal transduction, and endocytosis [9, 10].
Glycans were also found to be involved in the patho-
physiology of some major diseases, such as inflammatory
diseases and cancers [11–13]. Glycans have a particularly
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important role in the immune system, and glycosylation
may affect the function of the immune system on mul-
tiple levels [13, 14]. As glycans do not have a direct gen-
etic template, glycan structures are determined by
complex dynamic interactions between a number of gen-
etic and environmental factors [15, 16]. These unique
qualities have promoted interest in the role and use of
N-glycans as potential predictors of the development of
complex diseases such as IS.
Immunoglobulin G (IgG) plays an important role in
the human immune system, and N-glycans attach to the
conserved asparagine 297 in the fragment crystallizable
(Fc) region and act as a switch between pro- and anti-
inflammatory IgG functionality [17]. Changes in IgG gly-
cosylation are not only involved in several inflammatory
diseases [18–21] but also can be a part of the molecular
mechanism leading to the promotion of inflammation
[22–24]. The inflammatory role of IgG N-glycosylation,
together with its association with the risk factors of is-
chemic stroke, such as aging, obesity, dyslipidemia, type
2 diabetes (T2D), and hypertension [25–28], led us to
hypothesize that the changes in IgG N-glycan profiles
are involved in the pathogenesis of IS by regulating the
inflammatory response.
In this study, we investigated the association of IgG
N-glycan profiles with CAS and IS to provide bio-
markers for the screening of CAS and IS. In addition, we
aimed to determine the association between IgG N-gly-
come and markers of inflammation, including C-reactive
protein (CRP), tumor necrosis factor-alpha (TNF-α), and
matrix metalloproteinase-9 (MMP9), to further elucidate
the roles of IgG glycosylation on CAS and IS.
Methods
Participants
All participants were recruited from the Jidong Oil-field
Hospital, Chinese National Petroleum, and the Tiantan
Hospital, Capital Medical University from September
2009 to September 2013 [29, 30]. All participants were re-
quired to meet the following inclusion criteria: (1) signed
informed consent prior to participation; (2) 18 years or
older aged equal to or greater than 18 years old. Individ-
uals were excluded based on the following criteria: (1)
pregnant or lactating women; (2) history of mental illness
or infectious disease; (3) history of aneurysm caused by
cerebral infarction, cerebral hemorrhage or other cerebro-
vascular diseases, congenital heart disease, acute myocar-
dial infarction, liver disease, renal failure, malignant
tumor, chronic obstructive pulmonary disease, rheumatoid
arthritis, or other diseases; and (4) history of medications
during the preceding 2 weeks in the controls. Written in-
formed consent was obtained from each subject at the be-
ginning of the study.
Diagnosis of IS and CAS
IS patients, diagnosed according to the International
Classification of Disease (9th revision, codes 430 to 438)
on the basis of history, clinical symptoms, physical
examination, and cranial computed tomography (CT) or
magnetic resonance imaging (MRI) [31], were included
in this study. CAS was diagnosed based on the level of
the vessel stenosis according to the established criteria
[30, 32]. The age- and sex-matched controls were de-
fined as no history of CAS and stroke and no family his-
tory of stroke.
Covariates
Demographic characteristics of participants, including age,
gender, and ethnicity, were collected by a questionnaire.
Detailed information about demographic characteristics
has been described previously [29, 30]. Weight and height
measurements were carried out with the participants
wearing only light indoor clothing and without shoes. The
body mass index (BMI) was calculated by the formula
weight (in kilograms)/height2 (in meters squared). Obesity
is defined as BMI > 28.0 kg/m2 [33]. Systolic blood
pressure (SBP) and diastolic blood pressure (DBP) were
measured twice on the right arm using a standard
mercury sphygmomanometer on set with the subjects
resting at least 10 min in a sitting position (World Health
Organization (WHO), [34]). The participants were then
classified into the hypertension group (mean SBP ≥
140 mmHg or mean DBP ≥ 90 mmHg) or the normal
blood pressure group (mean SBP < 120 mmHg and mean
DBP < 80 mmHg) [34].
After an overnight fasting, two tubes of blood (5 mL)
were collected in the morning by venipuncture. One
sample was taken in vacuum negative pressure tubes not
containing ethylene diamine tetraacetic acid (EDTA) to
acquire serum (2 mL), which was used to measure the
blood biochemistry indexes and inflammatory mediators,
and the other sample was taken in vacuum negative
pressure tubes containing EDTA. Then, the whole blood
was centrifuged at 3000 rpm for 10 min, and the plasma
(3 mL) was separated which was used to detect N-glyco-
mic. All collected blood samples were processed within
8 h and stored at − 80 °C until further measurement.
The fasting blood glucose (FBG) concentrations were
measured by the glucose oxidase-peroxidase method
(Mind Bioengineering Co. Ltd., Shanghai, China).
Diagnosis of T2D was made by physicians according to
the 1999 WHO Criteria (FBG greater than or equal to 7.
0 mmol/L) [35]. Serum total cholesterol (TC), triglycer-
ides (TG), high-density lipoprotein (HDL) cholesterol,
and low-density lipoprotein (LDL) cholesterol were mea-
sured using previously described methods with an
Olympus Automatic Biochemical Analyzer (Hitachi 747;
Hitachi, Tokyo, Japan). According to the guideline for
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the prevention and control of dyslipidemia of adults in
China [36], the participants were grouped into dyslipid-
emia with TC ≥ 6.2 mmol/L, or TG ≥ 2.3 mmol/L, or
HDL < 1.0 mmol/L, or LDL ≥ 4.1 mmol/L.
Measurement of inflammatory mediators
The level of inflammatory mediators in the serum was
measured using the relevant enzyme-linked immunosorb-
ent assay (ELISA) kit for CRP, TNF-α, and MMP9. The in-
flammatory mediators were detected in accordance with
the protocols from the CRP kit (R&D Systems,
Bio-Techne China Co. Ltd., Beijing, China), TNF-α kit
(R&D Systems, Bio-Techne China Co. Ltd., Beijing,
China), and MMP9 kit (R&D Systems, Bio-Techne China
Co. Ltd., Beijing, China) as previously reported [37].
IgG N-glycans analysis
As previously reported, IgG was isolated from human
plasma firstly [38]. In brief, after washing and equili-
brating protein G monolithic plates, 50 μL of plasma
was diluted 10× with binding buffer (1× phosphate-
buffered saline, pH 7.4), applied to the protein G plates,
and washed instantly. IgGs were eluted with 1 mL of 0.
1 M formic acid and immediately neutralized with 1 M
ammonium bicarbonate. Then, IgG N-glycans were
released and labeling was performed. The released
N-glycans were labeled with 2-aminobenzamide, a
fluorescent dye used to make glycans visible by ultra-
performance liquid chromatography (UPLC), by multi-
stage mixing with 2-aminobenzamide, dimethylsulfox-
ide, glacial acetic acid, and 2-picoline borane. In the
end, IgG N-glycans were analyzed by hydrophilic
interaction chromatography (HILIC)-UPLC into 24 IgG
glycan peaks (GPs) [38]. The glycan structures of the
most abundant glycans per peak were reported
previously [25].
All chromatograms were separated in the same man-
ner into 24 peaks, and the amount of glycans in each
peak was expressed as a percentage of total integrated
area. An additional 54 derived traits describing the rela-
tive abundances of galactosylation, sialylation, bisecting
GlcNAc, and core fucosylation were calculated by the
remaining 24 directly measured glycans. Of the derived
traits, 40 were of interest and included in the analysis.
Normalization and batch correction of UPLC data were
detailed in a published study [38].
Statistical analysis
Normality distributions of inflammation markers and
glycans were tested by the Kolmogorov–Smirnov tests,
of which p < 0.10 was considered statistically significant.
Continuous variables underlying normal distribution
were represented as the mean ± standard deviation (SD);
otherwise, medians (P25− P75) were used. The differences
of continuous variables among three groups were tested
by one-way analysis of variance (ANOVA) or the Krus-
kal–Wallis test. Categorical variables were represented
as n (proportion), and the differences among the three
groups were tested by chi-square tests.
For markers of inflammation and most of the glycans
that were not normally distributed, normalized transfor-
mations were applied. The Kruskal–Wallis test was per-
formed to compare the differences of initial and derived
IgG glycans among the three groups. Multinomial logistic
regression was performed to identify 24 initial glycans and
54 derived glycans related to disease status, adjusting the
effect of age, sex, obesity, diabetes, hypertension, and dys-
lipidemia. The significant glycans were graphed by forest
plot, which was generated using the R package “forestplot.
” Then, a logistic regression model assessed the discrimin-
ation of IS, CAS, and the controls by combining the sig-
nificant glycans. As shown in Additional file 1: Figure S1,
the significant correlation coefficients in glycans ranged
from 0.145 to 0.845. There were internal associations
among glycans, which could induce multicollinearity in
the statistical models; therefore, the classical method of re-
gression, including ridge, lasso, and stepwise regression,
was used to select glycans to make dimension reduction
[39–41]. To evaluate the performance of the discrimin-
atory model, the 5-fold cross-validation procedure was
analyzed using the R package “boot.” The index of evalu-
ation was the false discrimination rates, which were used
to compare the method of dimension reduction. The
internal associations among glycans were analyzed using
the R package “corrplot.” A receiver operating characteris-
tic (ROC) curve was developed for the calculation of the
area under the curve (AUC) with a 95% confidence
interval (CI).
To investigate the relationship between markers of
inflammation and IgG N-glycans, a canonical correl-
ation analysis (CCA) was used to determine two set
variables of the initial glycan structures (x) and markers
of inflammation (y) and find those combinations which
were maximally correlated with each other [42]. The
identified variables with a statistically significant impact
on the canonical variables were judged by the canonical
loadings. Generally, the absolute values greater than 0.
30 are considered to be significant loadings. Since nor-
malized transformations were applied, linear correlation
was used to calculate the correlation coefficient of the
24 initial glycans with markers of inflammation.
Data analysis was performed using SPSS Statistics ver-
sion 21.0 for Windows (IBM Corp., Armonk, NY, USA),
SAS software version 9.2 (SAS Institute, Chicago, IL,
USA), and R version 3.3.2 (R Core Team 2016). All re-
ported p values were two-tailed, and p < 0.05 was consid-
ered statistically significant.
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Results
Participant characteristics
In total, 78 participants with IS, 75 with CAS, and 77
controls were included in the present study. The differ-
ences of demographic characteristics and inflammatory
parameters among the three groups were analyzed
(Table 1). The levels of BMI, SBP, CRP, TNF-α, and
MMP9 in the IS group were significantly higher than
those in the control group, whereas higher levels of TC
and LDL were found in the control group (p < 0.017).
The levels of CRP and MMP9 in the IS group were sig-
nificantly higher than those in the CAS group, whereas
higher levels of TC and LDL were found in the CAS
group (p < 0.017).
Association of IgG N-glycans with ischemic stroke
Of the 24 initial glycans, 12 were abnormally distributed
(p < 0.10) (Additional file 1: Table S1). Normalized
transformations were then applied. Statistically signifi-
cant differences in IgG glycome composition between
patients with IS compared with CAS and controls were
observed (Figs. 1 and 2, Additional file 1: Tables S2–S5),
while there was no significant difference between CAS
Table 1 Characteristics of the study subjects
Parameters Controls
(n = 77)
CAS
(n = 75)
IS
(n = 78)
p value*
Gender (male/female) 54/23 54/21 60/18 0.617
Age (years) 48.09 ± 8.42 48.79 ± 7.88 47.42 ± 13.02 0.735
BMI (kg/m2) 23.75 ± 2.85 24.92 ± 3.17 25.65 ± 4.50$ 0.005
FBG (mmol/L) 5.10 ± 0.52 5.14 ± 0.48 5.47 ± 2.19 0.169
SBP (mmHg) 119.35 ± 9.54 120.21 ± 9.65 124.86 ± 12.48$ 0.002
DBP (mmHg) 76.10 ± 8.43 78.52 ± 7.78 78.68 ± 8.45 0.115
TC (mmol/L) 4.49 ± 0.73 4.74 ± 0.84 3.84 ± 1.02$& < 0.001
TG (mmol/L) 1.49 ± 0.73 1.57 ± 0.96 1.70 ± 0.83 0.372
HDL (mmol/L) 1.22 ± 0.37 1.32 ± 0.31 1.09 ± 0.37& 0.048
LDL (mmol/L) 2.52 ± 0.50 2.68 ± 0.56 2.26 ± 0.85$ < 0.001
CRP (mg/L) 0.34 (0.22–0.57) 0.44 (0.22–0.86) 0.51 (0.27–1.73)$& < 0.001
TNF-α (ng/L) 12.06 (8.38–17.32) 11.63 (8.21–17.55) 18.52 (12.60–24.26)$ 0.041
MMP9 (mg/L) 0.34 (0.20–0.51) 0.23 (0.16–0.40) 0.87 (0.46–1.15)$& < 0.001
CAS cerebral arterial stenosis, IS ischemic stroke, BMI body mass index, FBG fasting blood glucose, SBP systolic blood pressure, DBP diastolic blood pressure, TC
total cholesterol, TG total triglycerides, HDL high-density lipoprotein, LDL low-density lipoprotein, CRP C-reactive protein, TNF-α tumor necrosis factor-alpha, MMP9
matrix metalloproteinase-9
*Statistically significant at a significant level of 0.05
#p < 0.017, CAS group compared with control group
$p < 0.017, IS group compared with control group
&p < 0.017, IS group compared with CAS group
Fig. 1 Odds ratios (OR) and 95% confidence intervals (95% CI) for the associations of the normalized glycan variables in IS versus the control
(adjusted for age, sex, obesity, diabetes, hypertension, and dyslipidemia)
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and controls (p > 0.05). In total, 10 initial glycans and six
derived glycans (glycosylation features of galactosylation,
sialylation, and bisecting GlcNAc) were different be-
tween the IS and control groups after adjusting for the
effects of gender, age, obesity, diabetes, hypertension,
and dyslipidemia (p < 0.05). Meanwhile, five initial gly-
cans and six derived glycans (glycosylation features of
galactosylation and sialylation) were different between
the IS and CAS groups after adjusting for the effects of
gender, age, obesity, diabetes, hypertension, and dyslipid-
emia (p < 0.05).
For the initial glycans, the levels of GP1 and GP8 in
the IS group were significantly higher than those in the
control group, whereas higher levels of GP5, GP13,
GP14, GP15, GP17, GP18, GP21, and GP23 were found
in the control group. For the derived glycans, the level
of bisecting GlcNAc (FBS2/FS2 and FBS2/(FS2 + FBS2))
in the IS group was significantly higher than that in the
control group, whereas higher levels of galactosylation
(G2n) and sialylation (FGS/(FG + FGS) and FGS/(F + FG
+ FGS)) were found in the control group.
Among the initial glycans, the levels of GP1 in the IS
group was significantly higher than those in the CAS
group, whereas higher levels of GP5, GP15, GP20 and
GP23 were found in the CAS group. For the derived gly-
cans, the level of galactosylation (G2n) and sialylation
(FG2S2/(FG2 + FG2S1 + FG2S2) and FBG2S1/(FBG2 +
FBG2S1 + FBG2S2)) in the IS group were significantly
lower than those in the CAS group.
Classification of ischemic stroke using IgG glycans
GP5, GP13, and GP23 were selected by ridge regression;
GP5, GP8, GP13, GP21, and GP23 were selected by step
regression; and GP1, GP5, GP8, GP13, GP17, GP21, and
GP23 were selected by lasso regression in the IS and
control groups. The three methods of the false discrim-
ination rates were 0.296, 0.304, and 0.272, respectively
(Additional file 1: Table S6). In the end, we chose step
regression to establish logistic regression models
incorporating the included glycans to distinguish IS
from controls, with AUC of 0.802 (95% CI, 0.732–0.
872) (Fig. 3). GP5 was selected by step regression in the
IS and CAS groups, with an AUC of 0.740 (95% CI, 0.
661–0.819) (Fig. 3).
Correlation between IgG glycosylation and inflammation
markers
The results of CCA showed that there were three pairs
of canonical variables, with canonical correlations of 0.
566 (F = 1.83, p < 0.001), 0.387 (F = 1.01, p = 0.467), and
0.243 (F = 0.56, p = 0.944) for each successive pair by the
CCA. The first canonical set was statistically significant,
indicating that N-glycan structures were significantly
correlated with the markers of inflammation. Moreover,
Fig. 2 Odds ratios (OR) and 95% confidence intervals (95% CI) for
the associations of the normalized glycan variables in IS versus CAS
(adjusted for age, sex, obesity, diabetes, hypertension,
and dyslipidemia)
Fig. 3 Receiver operating characteristic (ROC) curve analysis in regard to binary logistic regression in the prediction of IS by the control and CAS
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four initial traits (GP5, GP10, GP11, and GP23) tended
to be significantly associated with MMP9 and CRP levels
in the first canonical set (Fig. 4). In addition, the level of
GP11 was strongly associated with canonical variables
with the loading of 0.457, while the response variable
with the highest canonical loading was 0.952 (MMP9).
In addition, the Pearson product moment correlation
coefficients between N-glycan structures and inflamma-
tion markers are shown in Table 2. The inflammatory
state was positively correlated with GP4, GP6, GP10,
and GP11, while negatively correlated with GP5, GP14,
GP18, and GP23. The association between derived gly-
cans and markers of inflammation showed that low
levels of galactosylation and sialylation and high levels of
bisecting GlcNAc correspond with the state of inflam-
mation (Additional file 1: Table S7).
Discussion
Previous studies showed that IgG glycosylation is associ-
ated with the risk factors of IS, such as aging, obesity, dys-
lipidemia, T2D, and hypertension [25–28]. In this study,
we described the differences of glycosylation of IgG in IS
patients and compared these with CAS and the controls.
To our knowledge, this study is the first attempt to inves-
tigate the association of IS with IgG N-glycans.
We showed the high levels of GP1 and GP8 and low
levels of GP5, GP13, GP14, GP15, GP17, GP18, GP21,
and GP23 in IS patients compared with the controls.
GP1 and GP8 are agalactosylated and fucosylated gly-
cans, which are significantly higher in IS. In parallel,
GP13, GP14, and GP15, which have two galactoses and
share the derived trait G2n, are significantly lower in IS.
In addition, GP17, GP18, GP21, and GP23 that contain
Fig. 4 Canonical structures of initial IgG N-glycan and inflammation markers in the first canonical set. The absolute value of canonical loadings
greater than 0.30 was significant loadings. All of the variables are sorted by the absolute value of their canonical loadings. The positive relationships are
represented in black boxes, while negative relationships are showed in red boxes. CRP C-reactive protein, TNF-α tumor necrosis factor-alpha, MMP9
matrix metalloproteinase-9
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sialic acid are lower in IS. The changes of galactosylation
and sialylation for initial glycans are consistent with the
results of the association between the derived traits in
the IgG glycome and IS. The changes of derived glycans
indicate that the high level of bisecting GlcNAc can
increase the risk of IS. Although we did not identify the
differences of glycans between CAS and controls, the
differences of glycans in IS compared with CAS or the
controls were identified. The changes of glycans between
IS and CAS were less compared to the changes between
IS and controls, suggesting that there were some
changes of glycosylation in CAS compared with
controls. In the progression of IS, the faintly aberrant
IgG glycosylation in CAS might play a cascading role in
the pathogenesis of IS. Our findings also indicate that
the high level of bisecting GlcNAc and the low level of
galactosylation and sialylation may increase the risk of IS
compared with CAS and controls.
Abundant evidence has shown that the decreasing
galactosylation and sialylation and the increasing
bisecting GlcNAc are risk factors of many inflammatory
and chronic diseases [18–21, 25, 27, 28, 43, 44], which
is consistent with our present results (Table 3). As sum-
marized in Table 3, the decreased IgG galactosylation,
which was reported in a number of different inflamma-
tory and chronic diseases, might suggest that aberrant
glycosylation of IgG is not disease-specific, but a gen-
eral phenomenon associated with reducing the anti-
inflammatory function of circulating IgG. Studies have
shown that the absence of sialic acid dramatically
changes the physiological role of IgG, converting them
from anti-inflammatory to pro-inflammatory agents
[45]. So far, this evidence clearly shows that IgG glyco-
sylation plays a crucial role in modulating the antibody-
mediated response and could be a part of the molecular
mechanism leading to the promotion of inflammation.
In the present study, the association between IgG gly-
cosylation and inflammatory status showed that low
levels of galactosylation and sialylation and high levels
of bisecting GlcNAc correspond with the state of
inflammation.
The high levels of pro-inflammatory parameters
(CRP, TNF-α, and MMP9) in the IS group show that
inflammation might be one of the characteristics of
IS. This is supported by the fact that a chronic level
of inflammation is a known risk factor for IS [7].
Therefore, our finding that IS is associated with the
inflammatory status of IgG (lower of galactosylation
and sialylation and higher of bisecting GlcNAc) might
partly explain the inflammation accompanying the de-
velopment of IS.
The emergence and development of molecular
markers opens the “black box” of disease development.
N-glycosylation of human proteins is an essential post-
translational modification, which is closely related to
biological function, and may predict the occurrence
and development of diseases more accurately [10, 46].
However, there are many challenges to transfer glyco-
sylation biomarkers into clinical applications. As we
have shown (Table 3), the change of glycans (GP5,
GP8, GP17, and GP21) in several chronic diseases is
not consistent. To select biomarkers for a disease
screen, we first chose qualitative biomarkers to deter-
mine what conditions can increase the risk of disease.
In combination with previous studies (Tables 2 and 3),
we found that high level of GP1, GP2, GP4, and GP6
and low level of GP13, GP14, GP15, GP18, and GP23
can increase the risk of disease. Therefore, GP1-2,
GP4, GP6, GP13-15, GP18, and GP23 may be
Table 2 Associations between normalized initial glycans and
inflammation markers
Glycans CRP TNF-α MMP9 Inflammation
GP1 − 0.024 0.074 0.177** +&
GP2 0.202** 0.071 0.039 +&
GP3 0.070 0.155* − 0.141* /
GP4 0.144* 0.185** 0.013 +#
GP5 − 0.187** − 0.138* − 0.219** −#
GP6 0.202** 0.103 0.170** +#
GP7 0.038 − 0.057 − 0.042 /
GP8 0.106 0.065 0.067 /
GP9 0.009 0.005 − 0.006 /
GP10 0.146* − 0.008 0.198** +#
GP11 0.178** 0.008 0.244** +#
GP12 − 0.073 − 0.186** − 0.051 /
GP13 − 0.014 − 0.046 − 0.065 −&
GP14 − 0.216** − 0.198** − 0.094 −#
GP15 − 0.072 − 0.159* − 0.069 −&
GP16 0.073 0.017 0.108 /
GP17 − 0.084 − 0.110 − 0.077 /
GP18 − 0.156* − 0.165* − 0.036 −#
GP19 − 0.045 0.053 − 0.012 /
GP20 − 0.076 0.034 − 0.129 /
GP21 − 0.139* − 0.057 − 0.025 /
GP22 0.012 0.025 0.044 /
GP23 − 0.201** − 0.038 − 0.215** −#
GP24 − 0.021 0.074 − 0.017 /
# there are more than two significant and consistent inflammation markers. &
the result is a combination of previous studies. + the association between glycans
and inflammation is positive. − the association between glycans and inflammation
is negative. / the association between glycans and inflammation remains unclear.
CRP C-reactive protein, TNF-α tumor necrosis factor-alpha, MMP9
matrix metalloproteinase-9
*Correlation is significant at the 0.05 level
**Correlation is significant at the 0.01 level
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developed as clinically useful biomarkers for chronic
disease in the future.
In the present study, however, it is worth mentioning
GP5 which was incorporated into the two final discrim-
inatory models. In addition, only GP5 was used to dis-
criminate IS from CAS with AUC 0.740. From the
results of associations between initial glycans and
markers of inflammation, GP5 had a strong negative as-
sociation with inflammation. Based on these results, low
levels of GP5 can increase the risk of IS, which is con-
sistent with the association with Parkinson’s disease but
contrary to the association with colorectal cancer, sys-
temic lupus erythematosus, and dyslipidemia [18, 43]. A
possible explanation for this phenomenon could be that
IS and Parkinson’s are diseases of the nervous system
and have a common pathological basis of cerebral
arteriosclerosis [47–49]. In fact, GP5 is not only an agalac-
tosylated glycan but also a high-mannose N-linked glycan.
Studies have shown that high mannose can inhibit the in-
flammatory effect of macrophages and regulate the im-
mune system to exert anti-inflammatory effects, while
decrease in mannose levels can promote inflammatory ef-
fects [50]. In our present study, GP5 may be a special bio-
marker for the prevention or intervention of IS.
Although the inflammatory role of IgG N-glycosylation
associates with the increased risk of ischemic stroke, this
novel biomarker needs further validation in multiple-
ethnic population and the development of standard oper-
ating procedure before the practical utility in screening or
diagnosis of this disease. Besides the genome, epigenome,
Table 3 The change of glycans in diseases by UPLC
Glycans CRC UC CD SLE RA CKD PD HT T2D O DL* IS
GP1 ↑ – – ↑ ↑ – – – – – – ↑
GP2 ↑ – – ↑ ↑ ↑ – – – – ↑ –
GP3 ↑ – – – – – – – – – – –
GP4 ↑ ↑ ↑ ↑ – – – ↑ – – ↑ –
GP5 ↑ – – ↑ – – ↓ – – – ↑ ↓
GP6 ↑ ↑ ↑ ↑ – ↑ – ↑ ↑ – ↑ –
GP7 – – – ↑ – – – – – – – –
GP8 ↓ – – ↓ – – ↑ – ↓ – – ↑
GP9 ↓ ↓ ↓ ↓ – – – – ↓ – – –
GP10 ↓ – – ↑ – – – – ↑ – – –
GP11 ↓ – – – – – – – ↑ – ↑ –
GP12 ↓ – – ↑ – – – ↓ – – – –
GP13 ↓ – – – – – – ↓ – – – ↓
GP14 ↓ ↓ ↓ ↓ – ↓ ↑ ↓ – ↓ ↓ ↓
GP15 ↓ – – – – – – ↓ – – – ↓
GP16 ↑ – – ↓ – – – – – – – –
GP17 – – – ↑ – – ↓ – – – – ↓
GP18 ↓ ↓ ↓ ↓ – ↓ – ↓ – ↓ ↓ ↓
GP19 ↓ – ↓ ↑ – – – – – – – –
GP20 – – – – – – ↓ – – – ↑ –
GP21 – – – – – – ↓ – – – ↑ ↓
GP22 ↓ – – ↑ ↓ – ↓ – – – – –
GP23 – – – ↓ – – – – – – – ↓
GP24 – – – ↑ ↑ – – – – – – –
Galactosylation ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
Sialylation ↓ – ↓ ↓ – ↓ ↓ ↓ ↓ – ↓ ↓
Fucosylation ↑ – – ↓ ↑ – – ↓ ↓ – – –
Bisecting GlcNAc ↓ – ↑ ↑ – ↑ – ↑ ↑ – ↑ ↑
↑ high level of glycans can increase the risk of disease. ↓ low level of glycans can increase the risk of disease. CRC colorectal cancer, UC ulcerative colitis, CD
Crohn’s disease, SLE systemic lupus erythematosus, RA rheumatoid arthritis, CKD chronic kidney disease, PD Parkinson’s disease, HT hypertension, T2D type 2
diabetes, O obesity, DL dyslipidemia, IS ischemic stroke
*Unpublished paper
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transcriptome, proteome, and metabolome, the glycome
would supply new alternative for the screening of the bio-
markers. However, there are several common limitations
and insufficiencies, which should be recognized. First, the
differential glycosylation described above may provide ex-
citing insights into the pathogenesis of ischemic stroke.
However, causation is difficult to infer in data from those
already diagnosed with the condition, and the observed
changes may be consequences rather than causes of the
disease. Second, based on the fact that our study is a case-
control study, the selection bias cannot be ignored, which
could possibly lead to over-estimations of diagnostic ac-
curacy compared with a cross-sectional study or cohort
study. In addition, the exclusion criteria with history of
medications during the preceding 2 weeks are limited to
the controls but do not require the cases, which may trig-
ger the bias in estimation of measuring parameters. Also,
only three pro-inflammatory parameters (CRP, TNF-α, and
MMP9) were examined to represent inflammatory status,
which may induce evaluation bias. Finally, a possible ex-
planation for a failure to demonstrate the differences of
glycans between CAS and controls could be that the sam-
ple size is too small to identify the differences. Therefore,
further cross-sectional studies and cohort studies with
large samples are needed for the identification of diagnostic
biomarkers for ischemic stroke and a more definite explan-
ation about the relationships between N-glycan structures
and ischemic stroke based on our observation.
Conclusion
The present study showed that losses of galactose and si-
alic acid, as well as bisecting GlcNAc of IgG, might in-
volve in the molecular mechanism of inflammation,
which might be related to chronic inflammation that
accompanies the development of IS. Aberrant IgG glyco-
sylation might contribute to the pathogenesis of IS via
loss of pro- and anti-inflammatory balance, and thus,
IgG glycan profiles may be potential biomarkers for the
screening or risk stratification of IS.
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